Memantine Merz 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0021 
Minor change in labelling or package leaflet not 
16/02/2024 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
WS/2413/G 
This was an application for a group of variations 
25/05/2023 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
1234/2008. 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IG/1597/G 
This was an application for a group of variations. 
03/03/2023 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
A.7 - Administrative change - Deletion of 
manufacturing sites 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
WS/1980 
This was an application for a variation following a 
18/03/2021 
04/04/2022 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
WS/1579 
This was an application for a variation following a 
29/05/2019 
12/06/2020 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.e.1.a.2 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Semi-solid and non-sterile liquid 
pharmaceutical forms 
PSUSA/1967/
Periodic Safety Update EU Single assessment - 
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
201809 
memantine 
IG/0835/G 
This was an application for a group of variations. 
13/09/2017 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
R/0012 
Renewal of the marketing authorisation. 
18/05/2017 
13/07/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Memantine Merz in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IG/0768/G 
This was an application for a group of variations. 
06/03/2017 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IG/0767 
A.7 - Administrative change - Deletion of 
06/03/2017 
n/a 
manufacturing sites 
N/0011 
Minor change in labelling or package leaflet not 
23/01/2017 
13/07/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/1967/
Periodic Safety Update EU Single assessment - 
14/04/2016 
n/a 
PRAC Recommendation - maintenance 
201509 
memantine 
WS/0804 
This was an application for a variation following a 
25/02/2016 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
N/0009 
Minor change in labelling or package leaflet not 
01/12/2015 
13/07/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0007 
Minor change in labelling or package leaflet not 
29/07/2015 
13/07/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
WS/0668 
This was an application for a variation following a 
23/04/2015 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Following new data lock point, interim results of the 
Prostate Cancer study, 4 finalized studies and 
reformatting in compliance with the new template, 
submission of a revised and updated RMP version 7.1 
(delete). This RMP update also introduces changes to 
the required additional Pharmacovigilance activity 
regarding the identified potential risk of prostate 
cancer by adjusting the due dates of agreed 
milestones. The final RMP version is 7.2. 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/1967/
Periodic Safety Update EU Single assessment - 
10/04/2015 
n/a 
PRAC Recommendation - maintenance 
201409 
memantine 
IAIN/0006 
C.I.8.a - Introduction of or changes to a summary of 
02/02/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
WS/0562 
This was an application for a variation following a 
25/04/2014 
13/05/2015 
SmPC, Annex 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
and PL 
Update of section 4.6 of the SmPC for Axura and 
Memantine Merz with information currently included 
in section 5.3 referring to the absence of adverse 
effects noted on non-clinical male and female fertility 
studies, as per the QRD template. In addition, all the 
annexes have been brought in line with the QRD 
template version 9 and linguistic amendments have 
been introduced in some translations, including a 
correction of the list of excipients for Iron oxide in 
the German version.  The Croatian local 
representative has also been included in the package 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
leaflet. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
PSUSA/1967/
Periodic Safety Update EU Single assessment - 
10/04/2014 
n/a 
PRAC Recommendation - maintenance 
201309 
memantine 
IG/0260 
C.I.z - Changes (Safety/Efficacy) of Human and 
25/01/2013 
n/a 
Veterinary Medicinal Products - Other variation 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
